DK3116541T3 - Anvendelse af olie-og-vand-emulsioner til forøgelse af b-celleresponser med modificerede vaccinia-ankara-virus - Google Patents

Anvendelse af olie-og-vand-emulsioner til forøgelse af b-celleresponser med modificerede vaccinia-ankara-virus Download PDF

Info

Publication number
DK3116541T3
DK3116541T3 DK15721582.3T DK15721582T DK3116541T3 DK 3116541 T3 DK3116541 T3 DK 3116541T3 DK 15721582 T DK15721582 T DK 15721582T DK 3116541 T3 DK3116541 T3 DK 3116541T3
Authority
DK
Denmark
Prior art keywords
oil
increasing
application
cell responses
water emulsions
Prior art date
Application number
DK15721582.3T
Other languages
English (en)
Inventor
Cédric Cheminay
Robin Steigerwald
Ariane Volkmann
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK3116541T3 publication Critical patent/DK3116541T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15721582.3T 2014-03-12 2015-03-12 Anvendelse af olie-og-vand-emulsioner til forøgelse af b-celleresponser med modificerede vaccinia-ankara-virus DK3116541T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461951672P 2014-03-12 2014-03-12
PCT/EP2015/055239 WO2015136056A1 (en) 2014-03-12 2015-03-12 Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus

Publications (1)

Publication Number Publication Date
DK3116541T3 true DK3116541T3 (da) 2020-02-24

Family

ID=54070974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15721582.3T DK3116541T3 (da) 2014-03-12 2015-03-12 Anvendelse af olie-og-vand-emulsioner til forøgelse af b-celleresponser med modificerede vaccinia-ankara-virus

Country Status (4)

Country Link
US (1) US10653766B2 (da)
EP (1) EP3116541B1 (da)
DK (1) DK3116541T3 (da)
WO (1) WO2015136056A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
KR20220153587A (ko) 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301996A (nl) 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
IL161590A0 (en) 2001-12-10 2004-09-27 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
AU2006218115B2 (en) 2005-02-23 2012-08-02 Bavarian Nordic A/S Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
AT502275B8 (de) 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
EP2485725A2 (en) 2009-10-07 2012-08-15 Wyeth LLC Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
US20120328649A1 (en) 2010-09-23 2012-12-27 Baxter Healthcare S.A. Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus
GB201016471D0 (en) 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US10973892B2 (en) 2012-09-04 2021-04-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
CA2888367A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
JP6480875B2 (ja) 2013-03-15 2019-03-13 バヴァリアン・ノルディック・アクティーゼルスカブ 単一高用量のｍｖａは、新生児及び幼児において防御免疫応答を引き起こす

Also Published As

Publication number Publication date
WO2015136056A1 (en) 2015-09-17
US20170128561A1 (en) 2017-05-11
US10653766B2 (en) 2020-05-19
EP3116541A1 (en) 2017-01-18
EP3116541B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
CL2016002252A1 (es) Anticuerpos anti-egfrviii y usos de los mismos
BR112017009204A2 (pt) Derivados de feniltriazol hidroxialquil- substituído e usos dos mesmos
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3183505T3 (da) Underlag til positionering af varmeelementer og gulvanlæg
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3481838T3 (da) Nye fremgangsmåder til fremstillingen af oligonukleotider
BR112016016289A2 (pt) heteroaris e usos dos mesmos
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
BR112016020889A2 (pt) variantes de hppd e métodos de uso
DK3114447T3 (da) System til dynamisk bestemmelse af større jordområders varmeegenskaber
DK3365684T3 (da) Fremgangsmåde til berigelse af cellefrie nukleosomer
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3437359T3 (da) Fremgangsmåder til at styre relative målinger under nærvær af LBT
DK3072952T3 (da) Anvendelse af en ny køleolie
DK3254092T3 (da) Bestemmelse af en vægs termiske modstand
DK3436593T3 (da) Fremgangsmåder til varmeinaktivering af adenovirus
DK3114235T3 (da) Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3191498T3 (da) Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3569166T3 (da) Indretning til akut behandling af hjertestop
DK3230255T3 (da) Regulatorer af uhæmmet adfærd